Dyslipidemi

Artiklar

Se allt

PRALUENT is available as a unique,¥ once-monthly pen

Läs mer

Why choose PRALUENT^®?

The usual starting dose for PRALUENT is 75 mg administered subcutaneously once every 2 weeks. Patients requiring larger LDL-C reduction (>60%) may be started on 150 mg once every 2 weeks, or 300 mg once every 4 weeks (monthly), administered subcutaneously.²

Läs mer

Prevent the Event

Despite major advances in our understanding of atherosclerosis, ASCVD remains the leading cause of death globally.¹

Läs mer

Acute LDL-C reduction post ACS: Strike early and strike strong: From evidence to clinical practice

A clinical consensus statement of Association for acute cardiovascular care (ACVC), in collaboration with European association of preventive cardiology (EAPC) and the European Society of Cardiology working group on cardiovascular Pharmacotherapy Krychtiuk KA, et al. Eur Heart J Acute Cardiovasc Care. 2022;11(12):939–949.

Läs mer

Lipid management in patients with diabetes mellitus

Key principles of lipid management (LDL-C in particular) in accordance with the 2019 ESC/EAS Guidelines for the management of dyslipidaemias, and the 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.

Läs mer

Approach for patients with coronary artery disease (CAD): focus on LDL-C control

Läs mer

Approach for patients with peripheral artery disease (PAD) + T2DM: focus on LDL-C control

Läs mer

Cardiovascular diseases (CVDs) are the leading cause of death globally

Läs mer

Se allt

Utbildning

Se allt

Diabetes & Hjärta-kärl 2026 – Möten & Lärande

Under 2026 erbjuder vi en fortbildningsmöjlighet för dig som är läkare inom diabetesvård, kardiologi, lipidologi eller internmedicin – samt för dig som är diabetessjuksköterska eller sjuksköterska med särskilt intresse för sekundärprevention.

Läs mer